CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Randomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet ReactivityResults of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) Randomized Study
Young-Hoon Jeong, MD, PhD*,
Seung-Whan Lee, MD, PhD ,
Bong-Ryong Choi, MD*,
In-Suk Kim, MD, PhD ,
Myung-Ki Seo, MD*,
Choong Hwan Kwak, MD, PhD*,
Jin-Yong Hwang, MD, PhD* and
Seong-Wook Park, MD, PhD ,*
* Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea
Department of Laboratory Medicine, Gyeongsang National University Hospital, Jinju, Korea
Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Manuscript received August 11, 2008;
revised manuscript received December 2, 2008,
accepted December 8, 2008.
* Reprint requests and correspondence: Dr. Seong-Wook Park, Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, 388-1 Pungnap-dong, Songpa-gu, Seoul 138-736, Korea (Email: swpark{at}amc.seoul.kr).
Objectives: The purpose of this study was to determine the impact of adjunctive cilostazol in patients with high post-treatment platelet reactivity (HPPR) undergoing coronary stenting.
Background: Although addition of cilostazol to dual antiplatelet therapy enhances adenosine diphosphate (ADP)-induced platelet inhibition, it is unknown whether adjunctive cilostazol can reduce HPPR.
Methods: Sixty patients with HPPR after a 300-mg loading dose of clopidogrel were enrolled. HPPR was defined as maximal platelet aggregation (Aggmax) >50% with 5 µmol/l ADP. Patients were randomly assigned to receive either adjunctive cilostazol (triple group; n = 30) or high maintenance dose (MD) clopidogrel (high-MD group; n = 30). Platelet function was assessed at baseline and after 30 days with conventional aggregometry and the VerifyNow assay.
Results: Baseline platelet function measurements were similar in both groups. After 30 days, significantly fewer patients in the triple versus high-MD group had HPPR (3.3% vs. 26.7%, p = 0.012). Percent inhibitions of 5 µmol/l ADP-induced Aggmax and late platelet aggregation (Agglate) were significantly greater in the triple versus high-MD group (51.1 ± 22.5% vs. 28.0 ± 18.5%, p < 0.001, and 70.9 ± 27.3% vs. 45.3 ± 23.4%, p < 0.001, respectively). Percent inhibitions of 20 µmol/l ADP-induced Aggmax and Agglate were consistently greater in the triple versus high-MD group. Percent change of P2Y12 reaction units demonstrated a higher antiplatelet effect in the triple versus high-MD group (39.6 ± 24.1% vs. 23.1 ± 29.9%, p = 0.022).
Conclusions: Adjunctive cilostazol reduces the rate of HPPR and intensifies platelet inhibition as compared with a high-MD clopidogrel of 150 mg/day.
Key Words: platelet high post-treatment platelet reactivity adjunctive cilostazol high maintenance dose clopidogrel
|
Abbreviations and Acronyms
| | ACS = acute coronary syndrome | | ADP = adenosine diphosphate | | Agglate
= late platelet aggregation at 5 min | | Aggmax
= maximal platelet aggregation | | cAMP = cyclic adenosine monophosphate | | HPPR = high post-treatment platelet reactivity | | IPA = inhibition of platelet aggregation | | LD = loading dose | | LTA = light transmittance aggregometry | | MD = maintenance dose | | PCI = percutaneous coronary intervention | | PPP = platelet-poor plasma | | PRP = platelet-rich plasma | | PRU = P2Y12 reaction unit |
|
Related Article
-
Inside This Issue
J. Am. Coll. Cardiol. 2009 53: A24.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
D. P. Faxon
Women are like men ... Sometimes.
J. Am. Coll. Cardiol.,
November 17, 2009;
54(21):
1946 - 1948.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. P. Giugliano and E. Braunwald
The Year in Non-ST-Segment Elevation Acute Coronary Syndrome.
J. Am. Coll. Cardiol.,
October 13, 2009;
54(16):
1544 - 1555.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Cilostazol or High-Dose Clopidogrel for Platelet Resistance?
Journal Watch Cardiology,
May 6, 2009;
2009(506):
5 - 5.
[Full Text]
|
 |
|
|